ES2192128B1 - HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY. - Google Patents

HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY.

Info

Publication number
ES2192128B1
ES2192128B1 ES200100997A ES200100997A ES2192128B1 ES 2192128 B1 ES2192128 B1 ES 2192128B1 ES 200100997 A ES200100997 A ES 200100997A ES 200100997 A ES200100997 A ES 200100997A ES 2192128 B1 ES2192128 B1 ES 2192128B1
Authority
ES
Spain
Prior art keywords
human
monoclonal antibody
molecule
therapy
specifically recognizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100997A
Other languages
Spanish (es)
Other versions
ES2192128A1 (en
Inventor
Africa Gonzalez Fernandez
Monica Valladares Andrade
Ana Molina Ocaña
Francisco Gambon Deza
Susana Magadan Mompo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Vigo
Original Assignee
Universidade de Vigo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Vigo filed Critical Universidade de Vigo
Priority to ES200100997A priority Critical patent/ES2192128B1/en
Publication of ES2192128A1 publication Critical patent/ES2192128A1/en
Application granted granted Critical
Publication of ES2192128B1 publication Critical patent/ES2192128B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Anticuerpo monoclonal humano haIM-29 que reconoce la molécula humana CD69, y su uso en terapia humana. Un nuevo hibridoma, designado H69, productor de un anticuerpo monoclonal humano hAIM- 29 (de isotipo IgM / lambda). El anticuerpo reconoce de forma específica a la molécula humana CD69, que es un antígeno de activación muy temprano linfocitario. El hibridoma H69 se generó por fusión de células del mieloma murino NSO con células de bazo de un ratón transgénico portador de secuencias de inmunoglobulinas humanas que había sido inmunizado con una suspensión de células de rata transfectadas con la molécula humana CD69. El clon fue seleccionado por su patrón de reconocimiento celular por inmunofluorescencia indirecta frente a las células de rata transfectadas y frente a linfocitos activados humanos. La presente invención podría utilizarse para tratamiento de patologías humanas que conlleve gran activación linfocitaria (enfermedades autoinmunes como la artritis reumatoide u otras patologías de tipo inflamatorio).HaIM-29 human monoclonal antibody that recognizes the human CD69 molecule, and its use in human therapy. A new hybridoma, designated H69, producer of a human monoclonal antibody hAIM-29 (IgM / lambda isotype). The antibody specifically recognizes the human molecule CD69, which is a very early lymphocyte activation antigen. The H69 hybridoma was generated by fusion of NSO murine myeloma cells with spleen cells of a transgenic mouse carrying human immunoglobulin sequences that had been immunized with a suspension of rat cells transfected with the human CD69 molecule. The clone was selected for its pattern of cellular recognition by indirect immunofluorescence against transfected rat cells and against human activated lymphocytes. The present invention could be used for the treatment of human pathologies that entails great lymphocyte activation (autoimmune diseases such as rheumatoid arthritis or other inflammatory diseases).

ES200100997A 2001-04-27 2001-04-27 HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY. Expired - Fee Related ES2192128B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200100997A ES2192128B1 (en) 2001-04-27 2001-04-27 HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100997A ES2192128B1 (en) 2001-04-27 2001-04-27 HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY.

Publications (2)

Publication Number Publication Date
ES2192128A1 ES2192128A1 (en) 2003-09-16
ES2192128B1 true ES2192128B1 (en) 2005-01-01

Family

ID=28051947

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100997A Expired - Fee Related ES2192128B1 (en) 2001-04-27 2001-04-27 HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY.

Country Status (1)

Country Link
ES (1) ES2192128B1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244270A1 (en) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Immune regulation based on the targeting of early activation molecules
WO2004069183A2 (en) 2003-01-31 2004-08-19 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
NZ578635A (en) * 2006-12-26 2012-03-30 Ct De Inmunolgia Molecular Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
DK2993186T3 (en) 2008-03-14 2019-11-25 Biocon Ltd A monoclonal antibody and a method thereof
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0822830B1 (en) * 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANCHO D. et al. Functional Analysis of Ligand-Binding and Signal Transduction Domains of CD69 and CD23 C-Type Lectin Leukocyte Receptors. J. Immunol., Octubre 2000, Vol. 165, Nº 7, páginas 3868-3875. *

Also Published As

Publication number Publication date
ES2192128A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
Chu et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody
PT1425389E (en) Human antibodies specific for interleukin 15 (il-15)
HRP20181069T1 (en) Il-17 antagonistic antibodies
ES2514495T3 (en) Humanized anti-interleukin-18 modified antibodies
RU2010130994A (en) AGENTS AGAINST TARGET CELLS AIMED AT CD138 AND THEIR APPLICATION
PE20191546A1 (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 20H4.9 ANTI-41BB
AR079458A2 (en) CHEMICAL MONOCLONAL ANTIBODY THAT JOINS CD45
PE20120835A1 (en) ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES
DE69128253T2 (en) SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE
KR20100097724A (en) Anti-human il-21 monoclonal antibodies
RU2016151645A (en) SPECIFIC HETERODIMERIC DIANTISTS AND THEIR APPLICATION
NZ568403A (en) CD20-specific antibodies and methods of employing same
PE20030104A1 (en) HUMAN ANTIBODIES TO CD154
PE20090689A1 (en) ANTIBODIES OF ANTAGONIST OX40 AND ITS USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
RU2013152730A (en) ANTIBODIES TO OX-2 / CD200 AND THEIR APPLICATION
AR052065A1 (en) DIRECTED ANTIBODIES AGAINST ANGIOPOYETINA-2 AND USES OF THE SAME
RU2005132389A (en) HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNO DEPRESSIVE PROPERTIES
TW200513261A (en) Antibodies against interleukin-1 receptor and uses thereof
DK0812333T3 (en) Bispecific antibody which is effective in treating B-cell lymphoma and cell line
DK1272527T4 (en) PREPARATION OF ANTIBODIES WITH ADCC VIA CD16 AND IN PARTICULAR MONOCLONAL ANTI-RHESUS D ANTIBODIES
RU2007139953A (en) ANTIBODIES TO CCR5 AND THEIR APPLICATION
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ599497A (en) Humanized antibodies to amyloid beta
LU90383I2 (en) Simulect (inn: basiliximab)
RU2007140257A (en) MONOCLONAL ANTI-CD20-ANTIBODY

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030916

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192128B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20210803